Optimizing Treatment Strategies for Metastatic NSCLC: Achieving the Best Patient Outcomes 

Profiling a 58-year-old retired construction manager with Stage IV EGFR+ NSCLC, discussing his transition from osimertinib to amivantamab plus chemotherapy, managing side effects, and maintaining hope throughout his treatment journey.

Medical experts discuss strategies for educating patients on managing side effects of osimertinib and other EGFR inhibitors, with guidance on recognizing symptoms that warrant contacting their care team.

Strategies for managing cardiotoxicity in patients on osimertinib are discussed, focusing on monitoring adverse events and balancing symptom management with maintaining treatment efficacy.

Key opinion leaders examine approaches to managing skin-related side effects, such as rash, in patients on EGFR inhibitors, highlighting strategies to address quality-of-life impacts while maintaining the benefits of treatment.

Key opinion leaders discusses strategies for handling gastrointestinal side effects in patients taking osimertinib, including preventive measures and comparisons to managing GI issues from other EGFR inhibitors.

Key opinion leaders explores the management of gastrointestinal side effects in patients on osimertinib, focusing on preventive measures and comparisons with GI management strategies for other EGFR inhibitors.

Key opinion leaders highlight effective multidisciplinary strategies for managing the diverse range of side effects associated with EGFR inhibitors.

Key opinion leaders compare osimertinib's adverse event profile to other EGFR inhibitors, highlighting specific challenges and benefits observed in clinical practice

This is an actor portrayal of a hypothetical patient profile developed for educational purposes based on characteristics of patients with ALK+ non-small cell lung cancer as seen in clinical practice. The hypothetical case was co-developed by staff Medical Writers with Cancer Network/ONN

Key opinion leaders focus on educating patients about potential side effects of lorlatinib and other ALK inhibitors, including guidance on when to contact their care team.

Key opinion leaders explore strategies for managing neurotoxicity in patients on ALK inhibitors, emphasizing monitoring practices and balancing symptom management with treatment efficacy.

Key opinion leaders discuss experiences managing weight gain with lorlatinib, addressing its impact on quality of life versus treatment benefits.

Key opinion leaders examine how to manage gastrointestinal side effects in patients on lorlatinib, including preventive tips and comparisons with GI management strategies for other ALK inhibitors.

Key opinion leaders explore approaches to dose modifications or treatment pauses due to side effects, including examples where these adjustments significantly impacted patient outcomes.